-
Aishi Corporation announces China's listing of tyrosine kinase inhibitor LeWeima ®
Time of Update: 2020-06-10
liver cancer is the world's second leading cause of cancer-related death, with statistics for 2012 showing that about 750,000 people died from the disease worldwide in the year, as well as about 780
-
CHMP recommends approval of Lynparza as a single-drug therapy for adult patients with breast cancer
Time of Update: 2020-06-10
, the giant a pharmaceutical (http:// and partner Merck and Co announced in that the European (http:// Authority products for human medicine (http:// http:// Committee (CHMP) has issued a p
-
European Commission approves split dose scheme for Johnson and Johnson Darzalex
Time of Update: 2020-06-10
, the European Commission (EC) has approved Darzalex's split dose plan, the , a http:// company owned by the u.S pharmaceutical (http:// http:// ) giant, , announced the program will provide
-
Bayer's new gynaecological drug, Visanne, has been approved by Chinese regulators to treat endometriosis
Time of Update: 2020-06-10
, Germany's pharmaceutical (http:// giant Bayer announced that , the http:// new drug in the of gynaecology, , was approved by Chinese regulators for the treatment of endometriosis (EMs) Visanne
-
CHMP recommends neo-base Revlimid's triple therapy for the treatment of patients with multiple myeloma
Time of Update: 2020-06-10
recently, Celgene company (http:// announced that the European EMA human medicine (http:// product (http:// Committee (CHMP) recommended that the company's triple therapy based on Revlimid (
-
FDA grants CymaBay Therapeutics Clinical Phase 3 In Research Drug Seladelpar Breakthrough Therapy Determination
Time of Update: 2020-06-10
primary bile bile ductitis is a potentially life-threatening liver autoimmune disease As the immune system continues to attack bile ducts, bile flow is blocked and silted, toxic bile acid remains in
-
Lizhu Medicine "recombination of whole human source anti-OX40 monoclonal antibody injection" clinical trial application accepted by the State Drug Administration
Time of Update: 2020-06-10
recently, the Pharmaceutical (http:// announced that its holding affiliated company (http:// Zhuhai Lizhu single anti-biotechnology Co., Ltd declared "recombination of all-human source anti-OX
-
FDA approves Sanofi sugar-lowering drug Soliqua ® 100/33 expansion
Time of Update: 2020-06-10
recently, the U.S Food and Drug (http:// Administration ( FDA (http:// ) approved the expanded use of Sanofi's sugar-lowering drug Soliqua ® 100/33 (insulin glargine and lisine peptide injectio
-
Knopp Biosciences announces oral candidate drug dexpramipexole for FDA orphan drug designation
Time of Update: 2020-06-10
high eosinophil syndrome (HES) mainly refers to the patient's blood the number of eosinophils continued to increase (the absolute number of eosinophils is greater than 0.5 x 109/L), clinical manifes
-
FDA approves Janssen Pharmaceuticals Tremfya ® One Pres for treatment in adult patients with moderate to severe plaque psoriasis
Time of Update: 2020-06-10
recently, the U.S Pharmaceutical (http:// http:// giant , , janssen Pharmaceutical (http:// announced that the U.S FDA http:// has approved Tremfya ® One Press, a single-dose, patient-co
-
Diabetes innovative oral therapy imeglimin successfully in a Phase 3 clinical trial
Time of Update: 2020-06-10
recently, Poxel Bio Medicines (http:// http:// and partner Sumitomo Dayou Pharmaceutical son (http:// announced the success of its innovative diabetes innovation oral therapy, imeglimin, in
-
FDA approves shire's treatment of chronic isophation of Motegroity
Time of Update: 2020-06-10
CIC is a very common disease, the main symptoms are long-term defecation difficulties and infrequent, other symptoms include abdominal pain and bloating recently, the U.S FDA (http:// announced
-
FDA approves Pfizer Ibrance joint drug to treat male breast cancer patients
Time of Update: 2020-06-10
recently, Pfizer (http:// announced that the U.S FDA (http:// approved the company's heavy-weight breast cancer treatment Ibrcicsito in conjunction with aromatase inhibitors or fuforvestts to
-
Baiyang Pharmaceutical metformin new drug Nida in the United States approved by the FDA
Time of Update: 2020-06-10
recently, baiyang Pharmaceutical (http:// announced that the company (http:// of high-end generic drugs, the use of osmosis pump-controlled release technology metformin new drug (http:// th
-
Sanofi dengue vaccine Dengvaxia has been approved by the European Commission
Time of Update: 2020-06-10
dengue fever (Dengue) is an acute insect-borne infection caused by the mosquito-borne transmission of the dengue virus Clinical manifestations of high fever, headache, muscle, bone joint severe sore
-
A new drug application from FDA's new base, Lenalidomide, to naldomide
Time of Update: 2020-06-10
recently, bio pharmaceutical (http:// giant, Http:// announced that the u.S Food and Drug (http:// Administration ( FDA ( http:// had accepted and granted priority review to a application
-
ADHD reaches major endpoint in two key Phase 3 clinical trials
Time of Update: 2020-06-10
ADHD, commonly known as ADHD, is a chronic brain disease that manifests itself as unable to concentrate, hyperactivity and impulsiveness today, Supernus Pharmaceuticals (http:// announced that i
-
Advances in new research on the bioimmune anti-cancer drug YS-ON-001
Time of Update: 2020-06-10
Today, the company, the http:// Pharmaceutical (http:// Limited , announced http:// that the company's immuno-cancer drug (http:// YS-ON-001 has made new research progress, with excellent tum
-
Fda has janson TREMFYA ® One-Press for treatment of moderate to severe plaque psoriasis
Time of Update: 2020-06-10
recently http:// , the U.S FDA (http:// has approved the company's TREMFYA ® One-Press, a one-time, single-dose patient self-controlled syringe for the treatment of moderate to severe plaque psor
-
Xi'an Yangsen Yiyi (Ibtini capsule) New indications approved by the State Drug Administration
Time of Update: 2020-06-10
today, The of Johnson and Corporation (http:// Xi'an Yangsen Pharmaceutical Co., Ltd., a subsidiary of china's Pharmaceutical (http:// announced that its new indications of Eyre (ibitini capsu